A Companion Cancer Diagnostics is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person.
Companion Cancer Diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment with that particular drug on the basis of their biological characteristics that determine responders and non-responders to the therapy.
This report aims to provide a comprehensive presentation of the global market for Companion Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Companion Cancer Diagnostics. This report contains market size and forecasts of Companion Cancer Diagnostics in global, including the following market information:
- Global Companion Cancer Diagnostics Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global top five companies in 2022 (%)
The global Companion Cancer Diagnostics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Breast Cancer Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Companion Cancer Diagnostics include F. Hoffmann-La Roche, Agilent Technologies, QIAGEN, Abbott Laboratories, Almac Group, Danaher Corporation, bioM?rieuxSA and Myriad Genetics, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Companion Cancer Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Companion Cancer Diagnostics Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Companion Cancer Diagnostics Market Segment Percentages, by Type, 2022 (%)
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Melanoma
- Gastric Cancer
Global Companion Cancer Diagnostics Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Companion Cancer Diagnostics Market Segment Percentages, by Application, 2022 (%)
- Pharmaceutical & Biopharmaceutical Companies
- Reference Laboratories
- CROs
- Others
Global Companion Cancer Diagnostics Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Companion Cancer Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Companion Cancer Diagnostics revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Companion Cancer Diagnostics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- F. Hoffmann-La Roche
- Agilent Technologies
- QIAGEN
- Abbott Laboratories
- Almac Group
- Danaher Corporation
- bioM?rieuxSA
- Myriad Genetics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Companion Cancer Diagnostics, market overview.
Chapter 2: Global Companion Cancer Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Companion Cancer Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Companion Cancer Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
